Daniel S. Bejan
Impact in
- Biomaterials top 10%
- Nanoparticle-Based Drug Delivery
-
- Cancer Immunotherapy and Biomarkers
- PARP inhibition in cancer therapy
Papers in
- Oncology 11
- PARP inhibition in cancer therapy 9
- Cancer Immunotherapy and Biomarkers 2
-
- DNA Repair Mechanisms 2
- RNA Interference and Gene Delivery 2
- Co-authors
- Moataz Reda (7 shared papers)Wassana Yantasee (7 shared papers)Worapol Ngamcherdtrakul (7 shared papers)Joe W. Gray (5 shared papers)Natnaree Siriwon (4 shared papers)Molly A. Nelson (4 shared papers)Ruijie Wang (4 shared papers)Shenda Gu (2 shared papers)
- Journals
- Cell chemical biology (3 papers)The EMBO Journal (2 papers)Small (2 papers)Scientific Reports (1 paper)Chemical Science (1 paper)
- Partner nations
- United StatesCanadaThailand
In The Last Decade
Daniel S. Bejan
16 papers receiving 447 citations
Daniel S. Bejan's Hit Papers
Peers
Comparison fields: 5 of 56
- Biomaterials 97
- Oncology 174
- Immunology 104
- Biomedical Engineering 150
- Molecular Biology 217
Countries citing papers authored by Daniel S. Bejan
This map shows the geographic impact of Daniel S. Bejan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel S. Bejan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel S. Bejan more than expected).
Fields of papers citing papers by Daniel S. Bejan
This network shows the impact of papers produced by Daniel S. Bejan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel S. Bejan. The network helps show where Daniel S. Bejan may publish in the future.
Co-authors
The 25 scholars most cited alongside Daniel S. Bejan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment Hit paper breakdown → | 2022 | 140 |
| 2 | 2021 | 61 | |
| 3 | 2019 | 56 | |
| 4 | 2018 | 55 | |
| 5 | 2022 | 42 | |
| 6 | 2022 | 26 | |
| 7 | 2021 | 25 | |
| 8 | 2025 | 11 | |
| 9 | 2022 | 9 | |
| 10 | 2022 | 7 | |
| 11 | 2019 | 6 | |
| 12 | 2022 | 5 | |
| 13 | 2025 | 2 | |
| 14 | 2024 | 1 | |
| 15 | 2019 | 1 | |
| 16 | 2022 | 1 | |
| 17 | 2025 | 0 |
About Daniel S. Bejan
Daniel S. Bejan is a scholar working on Oncology, Molecular Biology, Electrical and Electronic Engineering, Biomaterials and Biomedical Engineering, having authored 17 papers that have together received 448 indexed citations. Recurring topics across this work include PARP inhibition in cancer therapy (9 papers), Integrated Circuits and Semiconductor Failure Analysis (4 papers), Nanoplatforms for cancer theranostics (3 papers), Nanoparticle-Based Drug Delivery (3 papers), Advancements in Semiconductor Devices and Circuit Design (3 papers), Cancer Immunotherapy and Biomarkers (2 papers), DNA Repair Mechanisms (2 papers) and RNA Interference and Gene Delivery (2 papers). The work is most often cited by research in Biomaterials (97 citations), Oncology (174 citations), Immunology (104 citations), Biomedical Engineering (150 citations) and Molecular Biology (217 citations). Daniel S. Bejan has collaborated with scholars based in United States, Canada and Thailand. Frequent co-authors include Moataz Reda, Wassana Yantasee, Worapol Ngamcherdtrakul, Joe W. Gray, Natnaree Siriwon, Molly A. Nelson, Ruijie Wang, Shenda Gu, Gordon B. Mills and Ngoc Ha Hoang. Their work appears in journals such as Cell chemical biology, The EMBO Journal, Small, Scientific Reports and Chemical Science.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.